1. Home
  2. FMN vs MDXH Comparison

FMN vs MDXH Comparison

Compare FMN & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Federated Hermes Premier Municipal Income Fund

FMN

Federated Hermes Premier Municipal Income Fund

N/A

Current Price

$10.05

Market Cap

85.2M

Sector

Finance

ML Signal

N/A

Logo MDxHealth SA

MDXH

MDxHealth SA

N/A

Current Price

$0.58

Market Cap

68.7M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
FMN
MDXH
Founded
2002
2003
Country
United States
Belgium
Employees
N/A
N/A
Industry
Investment Managers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
85.2M
68.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
FMN
MDXH
Price
$10.05
$0.58
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
★ $1.80
AVG Volume (30 Days)
55.7K
★ 200.4K
Earning Date
01-01-0001
11-12-2026
Dividend Yield
★ 3.86%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$5.40
Revenue Next Year
N/A
$12.92
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.77
$0.40
52 Week High
$11.76
$5.33

Technical Indicators

Market Signals
Indicator
FMN
MDXH
Relative Strength Index (RSI) 37.43 44.04
Support Level $9.77 $0.51
Resistance Level $11.32 $0.64
Average True Range (ATR) 0.16 0.04
MACD 0.02 -0.00
Stochastic Oscillator 36.67 51.98

Price Performance

Historical Comparison
FMN
MDXH

About FMN Federated Hermes Premier Municipal Income Fund

Federated Hermes Premier Municipal Income Fund is a United States-based diversified, closed-end management investment company. The investment objective of the fund is to provide current income exempt from federal income tax, including the federal alternative minimum tax by investing in long-term, tax exempt municipal bonds diversified among states, sectors and issuers. Its portfolio of investments comprises different sectors such as hospitals, toll road, senior care, airport, tobacco, and other sectors.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: